Form 4: Vivos Therapeutics CEO Reports Stock Transaction
Insider Transaction (Form 4)
Ronald Kirk Huntsman, Chief Executive Officer and a Director of Vivos Therapeutics, Inc., reported multiple transactions in common stock on June 30, 2026.
Summary
- Other acquisition/disposition: acquired 85,910 Preferred Stock at $0.58 ($50,000) on June 30, 2026; holds 85,910 after (Indirect).
- Other acquisition/disposition: acquired 85,910 Warrant (Right to Buy) at $0.58 ($50,000) on June 30, 2026; holds 85,910 after (Indirect).
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as routine: the reported changes are grants, option exercises, tax withholding or similar administrative transactions, which carry limited directional signal.
Insider Transactions
Ronald Kirk Huntsman — Director, Officer (Chief Executive Officer)
| Date | Transaction | Security | Shares | Price | Value | Held After |
|---|---|---|---|---|---|---|
| 2026-06-30 | Other acquisition/disposition | Preferred Stock | 85,910 | $1 | $50.0K | 85,910 |
| 2026-06-30 | Other acquisition/disposition | Warrant (Right to Buy) | 85,910 | $1 | $50.0K | 85,910 |
Key Dates
| Date | Description |
|---|---|
| 2026-06-30 | Other acquisition/disposition (85,910 shares) |
| 2026-06-30 | Other acquisition/disposition (85,910 shares) |
Keywords
insider transaction, Form 4, VVOS, Vivos Therapeutics, Inc., neutral, Ronald Kirk Huntsman
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.